Giulio Rossi, Luisella Righi, Francesca Barbisan, Marcello Tiseo, Paolo Spagnolo, Federica Grosso, Pasquale Pisapia, Umberto Malapelle, Marika Sculco, Irma Dianzani, Laura Abate-Daga, Maria Cristina Davolio, Giovanni Luca Ceresoli, Domenico Galetta, Giulia Pasello, Silvia Novello, Paolo Bironzo
The pathologic diagnosis of pleural mesothelioma is generally based on international guidelines, but no compulsory points based on different drugs approvals in different European countries are required to be reported. According to the last (2021) edition of the World Health Organization classification of pleural tumors, the nuclear grade of epithelioid-type mesothelioma should be always inserted in the pathologic report, while the presence of BRCA-associated protein-1 (BAP1) (clone C4) loss and a statement on the presence of the sarcomatoid/nonepithelioid component are fundamental for both a screening of patients with suspected BAP1 tumor predisposition syndrome and the eligibility to perform first-line immunotherapy at least in some countries...
April 8, 2024: Journal of Personalized Medicine